HKG: 3933

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

United Laboratories International Holdings Ltd (HKG: 3933) announced completion of a Phase II clinical trial for...

United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial

Fineline Cube Feb 4, 2026

United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products Administration (NMPA) has...

Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Fineline Cube Jan 29, 2026

United Laboratories International Holdings Ltd (HKG: 3933) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

United Laboratories Receives FDA Approval for Clinical Study of UBT37034 in Overweight/Obesity Treatment

Fineline Cube Jul 11, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that it has received...

Company Deals Drug

United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug

Fineline Cube Mar 25, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement...

Company Drug

United Laboratories’ UBT251 Receives FDA Green Light for Phase II CKD Study

Fineline Cube Mar 4, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that it has received approval...

Company Drug

United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA

Fineline Cube Jan 24, 2025

Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing...

Company Drug

United Laboratories’ UBT251 Approved for Phase II Trials in Chronic Kidney Disease

Fineline Cube Jan 23, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced receiving approval from the...

Company Drug

United Laboratories’ TUL12101 Eye Drops Enter Phase IIa Clinical Trial for Dry Eye Syndrome

Fineline Cube Oct 15, 2024

United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced the...

Drug

United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment

Fineline Cube Sep 27, 2023

United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that...

Company Drug

United Laboratories’ UBT251 Receives Tacit Approval for NAFLD Clinical Study in China

Fineline Cube Sep 11, 2023

Hong Kong firm United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category...

Company Drug

United Laboratories Receives Tacit Approval for JAK1 Inhibitor TUL01101 Clinical Trial

Fineline Cube Sep 11, 2023

Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced tacit clinical trial approval...

Company Drug

United Laboratories’ UBT251 Receives Tacit Approval for Obesity Clinical Study in China

Fineline Cube Sep 4, 2023

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category 1...

Company Drug

United Labs Gains NMPA Approval for Ozempic Biosimilar IND

Fineline Cube Oct 27, 2022

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products...

HKG: 3933

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

United Laboratories Receives FDA Approval for Clinical Study of UBT37034 in Overweight/Obesity Treatment

United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug

United Laboratories’ UBT251 Receives FDA Green Light for Phase II CKD Study

United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA

United Laboratories’ UBT251 Approved for Phase II Trials in Chronic Kidney Disease

United Laboratories’ TUL12101 Eye Drops Enter Phase IIa Clinical Trial for Dry Eye Syndrome

United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment

United Laboratories’ UBT251 Receives Tacit Approval for NAFLD Clinical Study in China

United Laboratories Receives Tacit Approval for JAK1 Inhibitor TUL01101 Clinical Trial

United Laboratories’ UBT251 Receives Tacit Approval for Obesity Clinical Study in China

United Labs Gains NMPA Approval for Ozempic Biosimilar IND

You Missed

Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen